Novartis Reconciled Depreciation vs Research Development Analysis

NVS Stock

USD 99.06 0.71 0.72%

Novartis financial indicator trend analysis is infinitely more than just investigating Novartis AG ADR recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novartis AG ADR is a good investment. Please check the relationship between Novartis Reconciled Depreciation and its Research Development accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

Reconciled Depreciation vs Research Development

Reconciled Depreciation vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novartis AG ADR Reconciled Depreciation account and Research Development. At this time, the significance of the direction appears to have weak relationship.

The correlation between Novartis' Reconciled Depreciation and Research Development is 0.32. Overlapping area represents the amount of variation of Reconciled Depreciation that can explain the historical movement of Research Development in the same time period over historical financial statements of Novartis AG ADR, assuming nothing else is changed. The correlation between historical values of Novartis' Reconciled Depreciation and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Reconciled Depreciation of Novartis AG ADR are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Reconciled Depreciation i.e., Novartis' Reconciled Depreciation and Research Development go up and down completely randomly.

Correlation Coefficient

0.32

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Reconciled Depreciation

Research Development

Most indicators from Novartis' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novartis AG ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

At this time, Novartis' Selling General Administrative is comparatively stable compared to the past year. Discontinued Operations is likely to gain to about 5.5 B in 2024, whereas Enterprise Value is likely to drop slightly above 107.4 B in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	37.0B	36.3B	34.2B	32.3B
Total Revenue	52.9B	51.8B	46.7B	46.2B

Gross Profit Total Revenue

Novartis fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Capital Stock
Total Assets		0.71	0.66	0.78	0.92	0.78	0.52	0.71	0.92	0.92	0.29	0.97	-0.28	0.12	0.7	-0.07	-0.26	-0.01	0.89	0.77	-0.05	0.0	0.88	0.43	0.41	-0.07
Short Long Term Debt Total	0.71		0.85	0.88	0.39	0.18	0.17	0.9	0.45	0.63	0.58	0.63	0.29	0.42	0.38	-0.4	-0.47	0.18	0.91	0.64	-0.15	-0.53	0.94	0.22	0.5	-0.4
Other Current Liab	0.66	0.85		0.96	0.36	0.18	0.04	0.7	0.39	0.74	0.61	0.5	0.07	0.6	0.26	-0.42	-0.52	0.39	0.74	0.68	0.16	-0.66	0.86	0.27	0.75	-0.44
Total Current Liabilities	0.78	0.88	0.96		0.5	0.36	0.11	0.75	0.52	0.83	0.58	0.66	-0.03	0.46	0.4	-0.36	-0.47	0.21	0.84	0.74	0.15	-0.5	0.94	0.34	0.66	-0.37
Total Stockholder Equity	0.92	0.39	0.36	0.5		0.9	0.65	0.43	0.99	0.83	0.07	0.92	-0.46	-0.05	0.71	0.12	-0.08	-0.08	0.66	0.65	-0.06	0.31	0.62	0.42	0.26	0.12
Property Plant And Equipment Net	0.78	0.18	0.18	0.36	0.9		0.46	0.28	0.84	0.76	-0.12	0.84	-0.63	-0.34	0.71	0.29	0.09	-0.32	0.53	0.59	0.06	0.48	0.48	0.45	0.02	0.3
Current Deferred Revenue	0.52	0.17	0.04	0.11	0.65	0.46		0.12	0.69	0.35	0.17	0.55	-0.36	-0.12	0.23	0.1	0.01	-0.26	0.33	0.12	-0.21	0.33	0.26	0.23	0.04	0.1
Net Debt	0.71	0.9	0.7	0.75	0.43	0.28	0.12		0.49	0.61	0.17	0.7	0.22	0.16	0.45	-0.25	-0.37	0.14	0.9	0.68	-0.14	-0.4	0.88	0.11	0.23	-0.25
Retained Earnings	0.92	0.45	0.39	0.52	0.99	0.84	0.69	0.49		0.82	0.11	0.92	-0.38	0.0	0.7	0.07	-0.13	-0.05	0.7	0.65	-0.12	0.24	0.65	0.41	0.27	0.06
Accounts Payable	0.92	0.63	0.74	0.83	0.83	0.76	0.35	0.61	0.82		0.29	0.88	-0.41	0.11	0.65	-0.12	-0.31	-0.01	0.79	0.76	0.14	-0.1	0.84	0.59	0.43	-0.12
Cash	0.29	0.58	0.61	0.58	0.07	-0.12	0.17	0.17	0.11	0.29		0.11	0.25	0.65	0.02	-0.45	-0.37	0.13	0.38	0.17	-0.07	-0.46	0.48	0.28	0.71	-0.44
Non Current Assets Total	0.97	0.63	0.5	0.66	0.92	0.84	0.55	0.7	0.92	0.88	0.11		-0.33	-0.13	0.74	0.02	-0.17	-0.2	0.87	0.71	-0.1	0.15	0.82	0.46	0.16	0.03
Non Currrent Assets Other	-0.28	0.29	0.07	-0.03	-0.46	-0.63	-0.36	0.22	-0.38	-0.41	0.25	-0.33		0.39	-0.04	-0.49	-0.41	0.26	0.01	-0.19	-0.57	-0.5	0.0	-0.29	0.12	-0.5
Cash And Short Term Investments	0.12	0.42	0.6	0.46	-0.05	-0.34	-0.12	0.16	0.0	0.11	0.65	-0.13	0.39		-0.21	-0.44	-0.4	0.81	0.16	0.25	0.13	-0.69	0.29	-0.19	0.91	-0.48
Net Receivables	0.7	0.38	0.26	0.4	0.71	0.71	0.23	0.45	0.7	0.65	0.02	0.74	-0.04	-0.21		-0.05	-0.26	-0.28	0.59	0.48	-0.5	0.29	0.53	0.61	0.04	-0.03
Common Stock Total Equity	-0.07	-0.4	-0.42	-0.36	0.12	0.29	0.1	-0.25	0.07	-0.12	-0.45	0.02	-0.49	-0.44	-0.05		0.96	-0.06	-0.2	-0.09	0.11	0.72	-0.28	-0.25	-0.35	1.0
Common Stock Shares Outstanding	-0.26	-0.47	-0.52	-0.47	-0.08	0.09	0.01	-0.37	-0.13	-0.31	-0.37	-0.17	-0.41	-0.4	-0.26	0.96		-0.07	-0.33	-0.22	0.16	0.66	-0.4	-0.31	-0.38	0.96
Short Term Investments	-0.01	0.18	0.39	0.21	-0.08	-0.32	-0.26	0.14	-0.05	-0.01	0.13	-0.2	0.26	0.81	-0.28	-0.06	-0.07		-0.02	0.25	0.22	-0.5	0.08	-0.42	0.67	-0.12
Non Current Liabilities Total	0.89	0.91	0.74	0.84	0.66	0.53	0.33	0.9	0.7	0.79	0.38	0.87	0.01	0.16	0.59	-0.2	-0.33	-0.02		0.7	-0.14	-0.25	0.97	0.32	0.35	-0.19
Inventory	0.77	0.64	0.68	0.74	0.65	0.59	0.12	0.68	0.65	0.76	0.17	0.71	-0.19	0.25	0.48	-0.09	-0.22	0.25	0.7		0.19	-0.16	0.75	0.27	0.47	-0.11
Other Current Assets	-0.05	-0.15	0.16	0.15	-0.06	0.06	-0.21	-0.14	-0.12	0.14	-0.07	-0.1	-0.57	0.13	-0.5	0.11	0.16	0.22	-0.14	0.19		-0.21	-0.02	-0.21	0.19	0.09
Other Stockholder Equity	0.0	-0.53	-0.66	-0.5	0.31	0.48	0.33	-0.4	0.24	-0.1	-0.46	0.15	-0.5	-0.69	0.29	0.72	0.66	-0.5	-0.25	-0.16	-0.21		-0.36	0.14	-0.54	0.74
Total Liab	0.88	0.94	0.86	0.94	0.62	0.48	0.26	0.88	0.65	0.84	0.48	0.82	0.0	0.29	0.53	-0.28	-0.4	0.08	0.97	0.75	-0.02	-0.36		0.34	0.49	-0.27
Property Plant And Equipment Gross	0.43	0.22	0.27	0.34	0.42	0.45	0.23	0.11	0.41	0.59	0.28	0.46	-0.29	-0.19	0.61	-0.25	-0.31	-0.42	0.32	0.27	-0.21	0.14	0.34		0.02	-0.21
Total Current Assets	0.41	0.5	0.75	0.66	0.26	0.02	0.04	0.23	0.27	0.43	0.71	0.16	0.12	0.91	0.04	-0.35	-0.38	0.67	0.35	0.47	0.19	-0.54	0.49	0.02		-0.38
Capital Stock	-0.07	-0.4	-0.44	-0.37	0.12	0.3	0.1	-0.25	0.06	-0.12	-0.44	0.03	-0.5	-0.48	-0.03	1.0	0.96	-0.12	-0.19	-0.11	0.09	0.74	-0.27	-0.21	-0.38

Click cells to compare fundamentals

Novartis Account Relationship Matchups

Novartis fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	118.4B	132.1B	131.8B	117.5B	99.9B	103.1B
Short Long Term Debt Total	29.3B	38.0B	31.1B	28.0B	26.3B	18.6B
Other Current Liab	15.4B	17.5B	18.0B	17.2B	15.1B	11.4B
Total Current Liabilities	28.3B	33.1B	30.2B	28.7B	26.4B	22.0B
Total Stockholder Equity	55.5B	56.6B	67.7B	59.3B	46.7B	57.2B
Property Plant And Equipment Net	13.7B	13.9B	13.1B	12.2B	10.9B	13.5B
Current Deferred Revenue	236M	114M	56M	123M	98M	135.9M
Net Debt	18.2B	28.4B	18.7B	20.4B	13.0B	11.0B
Retained Earnings	59.3B	57.2B	71.0B	63.5B	49.6B	57.8B
Accounts Payable	5.4B	5.4B	5.6B	5.1B	4.9B	4.2B
Cash	11.1B	9.7B	12.4B	7.5B	13.4B	7.7B
Non Current Assets Total	88.9B	102.4B	86.1B	80.5B	69.5B	73.2B
Non Currrent Assets Other	738M	892M	2.2B	1.1B	2.2B	2.1B
Cash And Short Term Investments	11.4B	11.6B	28.3B	18.9B	14.0B	13.1B
Net Receivables	8.6B	8.5B	8.3B	8.3B	9.4B	8.8B
Common Stock Total Equity	969M	944M	936M	913M	821.7M	776.8M
Common Stock Shares Outstanding	2.3B	2.3B	2.3B	2.2B	2.1B	1.9B
Short Term Investments	334M	1.9B	15.9B	11.4B	569M	540.6M
Liabilities And Stockholders Equity	118.4B	132.1B	131.8B	117.5B	99.9B	103.1B
Non Current Liabilities Total	34.6B	42.3B	33.8B	29.4B	26.8B	23.6B
Inventory	6.0B	7.1B	6.7B	7.2B	5.9B	6.0B
Other Current Assets	2.7B	2.5B	2.4B	2.5B	1.2B	2.2B
Other Stockholder Equity	(59.4B)	(57.2B)	(71.0B)	(63.6B)	(49.7B)	(47.2B)
Total Liab	62.8B	75.4B	64.0B	58.0B	53.2B	45.6B
Property Plant And Equipment Gross	13.7B	13.9B	13.1B	12.2B	22.8B	14.0B
Total Current Assets	29.5B	29.7B	45.7B	36.9B	30.5B	29.9B
Capital Stock	936M	913M	901M	890M	825M	767.6M
Short Term Debt	7.3B	10.1B	6.6B	6.2B	6.3B	6.3B
Common Stock	936M	913M	901M	890M	825M	767.6M
Accumulated Other Comprehensive Income	54.6B	55.7B	66.8B	58.5B	45.9B	52.6B
Intangible Assets	28.8B	36.8B	34.2B	31.6B	26.9B	22.4B
Other Liab	12.5B	14.4B	9.2B	7.6B	8.7B	8.5B
Other Assets	14.8B	14.7B	12.4B	4.8B	5.6B	10.1B
Long Term Debt	20.4B	26.3B	22.9B	20.2B	18.4B	12.8B
Good Will	26.5B	30.0B	29.6B	29.3B	23.3B	22.0B
Treasury Stock	(69M)	(80M)	(53M)	(48M)	(41M)	(43.1M)
Property Plant Equipment	13.7B	13.9B	13.1B	12.2B	14.0B	14.0B
Net Tangible Assets	5.6B	(5.5B)	9.4B	2.8B	2.5B	2.4B
Noncontrolling Interest In Consolidated Entity	77M	68M	167M	81M	83M	93.5M
Deferred Long Term Liab	5.4B	4.7B	5.5B	4.4B	5.1B	5.8B

Novartis Investors Sentiment

The influence of Novartis' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Novartis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to Novartis' public news can be used to forecast risks associated with an investment in Novartis. The trend in average sentiment can be used to explain how an investor holding Novartis can time the market purely based on public headlines and social activities around Novartis AG ADR. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Novartis' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Novartis' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Novartis' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Novartis.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Novartis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Novartis' short interest history, or implied volatility extrapolated from Novartis options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Novartis AG ADR is a strong investment it is important to analyze Novartis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Novartis' future performance. For an informed investment choice regarding Novartis Stock, refer to the following important reports:

How To Invest In Novartis

Details

Is Novartis Stock a good investment?

Details

What is Novartis' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Complementary Tools for Novartis Stock analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.

	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum

Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.215

Dividend Share

3.919

Earnings Share

4.4

Revenue Per Share

23.168

Quarterly Revenue Growth

0.097

The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Novartis Reconciled Depreciation vs Research Development Analysis

Reconciled Depreciation vs Research Development

Reconciled Depreciation vs Research Development Correlation Analysis

Correlation Coefficient

Reconciled Depreciation

Research Development

Novartis fundamental ratios Correlations

Novartis Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Novartis fundamental ratios Accounts

Novartis Investors Sentiment

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Novartis Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Stock	+ 1.0	Common Stock Total Equity
Retained Earnings	+ 0.99	Total Stockholder Equity
Non Current Assets Total	+ 0.97	Total Assets
Total Liab	+ 0.97	Non Current Liabilities Total
Total Current Liabilities	+ 0.96	Other Current Liab
Common Stock Shares Outstanding	+ 0.96	Common Stock Total Equity

Other Stockholder Equity	- 0.69	Cash And Short Term Investments
Other Stockholder Equity	- 0.66	Other Current Liab
Non Currrent Assets Other	- 0.63	Property Plant And Equipment Net
Other Current Assets	- 0.57	Non Currrent Assets Other
Total Current Assets	- 0.54	Other Stockholder Equity
Other Stockholder Equity	- 0.53	Short Long Term Debt Total